Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 ≥ 50 cells/mm3

Table 4 Cox regression of possible risk factors for achieving undetectable plasma HIV RNA at 48 weeks

Risk factors	HR	95% CI	P value
Age	1.000	0.980–1.020	0.993
Gender	0.948	0.661–1.513	0.774
Weight	0.998	0.983–1.013	0.778
Previous OIs	0.979	0.660–1.451	0.916
Hemoglobin	1.000	1.000–1.000	0.533
Baseline CD4 cell counts<50 cells/mm³	1.000	0.998–1.002	0.880
Baseline log plasma HIV-RNA	0.764	0.549–1.064	0.111

ISSN: 1742-6405